A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Erasca, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,291,000 shares of ERAS stock, worth $3.38 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,291,000
Previous 1,575,100 18.04%
Holding current value
$3.38 Million
Previous $3.72 Million 5.19%
% of portfolio
0.01%
Previous 0.01%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$2.17 - $3.28 $616,497 - $931,848
-284,100 Reduced 18.04%
1,291,000 $3.52 Million
Q2 2024

Aug 09, 2024

SELL
$1.79 - $2.63 $101,135 - $148,595
-56,500 Reduced 3.46%
1,575,100 $3.72 Million
Q1 2024

May 13, 2024

SELL
$1.67 - $2.55 $629,423 - $961,094
-376,900 Reduced 18.77%
1,631,600 $3.36 Million
Q4 2023

Feb 13, 2024

BUY
$1.67 - $2.49 $2.11 Million - $3.15 Million
1,266,400 Added 170.65%
2,008,500 $4.28 Million
Q3 2023

Nov 14, 2023

SELL
$1.97 - $2.91 $806,912 - $1.19 Million
-409,600 Reduced 35.56%
742,100 $1.46 Million
Q2 2023

Aug 11, 2023

SELL
$2.57 - $3.3 $786,394 - $1.01 Million
-305,990 Reduced 20.99%
1,151,700 $3.18 Million
Q1 2023

May 12, 2023

BUY
$2.74 - $4.44 $3.02 Million - $4.9 Million
1,103,115 Added 311.11%
1,457,690 $4.39 Million
Q4 2022

Feb 13, 2023

BUY
$3.89 - $8.57 $1.38 Million - $3.04 Million
354,575 New
354,575 $1.53 Million
Q2 2022

Aug 12, 2022

BUY
$4.58 - $8.72 $533,570 - $1.02 Million
116,500 Added 549.53%
137,700 $767,000
Q1 2022

May 13, 2022

BUY
$8.6 - $15.48 $182,320 - $328,176
21,200 New
21,200 $182,000

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $320M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.